Yarahmadi Amir, Sohan Romoye, McAllister Brenna, Caromile Leslie A
Vascular and Endovascular Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Center for Vascular Biology, University of Connecticut Health Center, Farmington, CT, USA.
Mol Cell Oncol. 2022 Oct 24;9(1):2136476. doi: 10.1080/23723556.2022.2136476. eCollection 2022.
Prostate cancer (PC) is a commonly diagnosed malignancy in men and is associated with high mortality rates. Current treatments for PC include surgery, chemotherapy, and radiation therapy. However, recent advances in targeted delivery systems have yielded promising new approaches to PC treatment. As PC epithelial cells express high levels of prostate-specific membrane antigen (PSMA) on the cell surface, new drug conjugates focused on PSMA targeting have been developed. microRNAs (miRNAs) are small noncoding RNAs that regulate posttranscriptional gene expression in cells and show excellent possibilities for use in developing new therapeutics for PC. PSMA-targeted therapies based on a miRNA payload and that selectively target PC cells enhances therapeutic efficacy without eliciting damage to normal surrounding tissue. This review discusses the rationale for utilizing miRNAs to target PSMA, revealing their potential in therapeutic approaches to PC treatment. Different delivery systems for miRNAs and challenges to miRNA therapy are also explored.
前列腺癌（PC）是男性中常见的诊断出的恶性肿瘤，且与高死亡率相关。目前PC的治疗方法包括手术、化疗和放射治疗。然而，靶向递送系统的最新进展为PC治疗带来了有前景的新方法。由于PC上皮细胞在细胞表面高水平表达前列腺特异性膜抗原（PSMA），因此已开发出专注于PSMA靶向的新型药物偶联物。微小RNA（miRNA）是小的非编码RNA，其调节细胞中的转录后基因表达，并在开发PC新疗法方面显示出极好的应用可能性。基于miRNA载荷且选择性靶向PC细胞的PSMA靶向疗法可提高治疗效果，而不会对周围正常组织造成损伤。本综述讨论了利用miRNA靶向PSMA的基本原理，揭示了它们在PC治疗方法中的潜力。还探讨了miRNA的不同递送系统以及miRNA治疗面临的挑战。
Zotero 插件